Preview

V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY

Advanced search

Tolerability of antidementive therapy: results of observational research

https://doi.org/10.31363/2313-7053-2018-2-117-124

Abstract

Tere are 44 patients (5 males and 39 females), aged 56 to 90 years were included in the study. To assess the tolerability and safety of the drug, undesirable events were recorded, associated and not associated with taking the drugwith taking the drug, a physical examination of patients was performed, an ECG was recorded and a biochemical blood test was performed at each visit of the patient to the center. During the observation period, two undesirable events chronologically associated with taking the drug were recorded During the study, none of the patients was excluded from the program due to the development of side effects and none of the patients refused to take the drug. We did not fnd any statistically signifcant increase in the incidence of cardiac pathology in patients taking the study drug, nor worsening of the already existing symptoms on the background of taking the drug for six months. Te observed growth trends in the level of blood creatinine a give grounds to recommend monitoring of kidney function in the patients taking the drug. In general, noogerone showed good tolerability, despite the elderly age of its patients and the high prevalence of concomitant somatic diseases in the sample.

About the Authors

N. M. Zalutskaya
«Bekhterev National Medical Research Psychiatry and Neurology Center
Russian Federation


I. A. Beltceva
«Bekhterev National Medical Research Psychiatry and Neurology Center
Russian Federation


N. G. Neznanov
«Bekhterev National Medical Research Psychiatry and Neurology Center
Russian Federation


References

1. Белоусов Ю.Б., Чикина Е.С., Медников О.И. Фармакоэкономические аспекты лечения деменции в РФ. — «РМЖ». — 2005. — № 20. — Т. 18.—С. 96-102.

2. Белоусов Ю.В., Зырянов С.К., Белоусов Д.Ю., Бекетов А.С. Социальные и экономические аспекты терапии болезни Альцгеймера в России. — Качественная клиническая практика. — 2009. — T.1. — C.3-28.

3. Залуцкая Н.М., Бельцева Ю.А., Незнанов Н.Г. Динамика когнитивного и социального функционирования пациентов с болезнью Альцгеймера на фоне терапии антидементивными препаратами: результаты наблюдательного исследования. — Обозрение психиатрии и медицинской психологии.—2016.—№ 4.—С.102-109.

4. Министерство здравоохранения и социального развития РФ, Федеральное государственное бюджетное учреждение «Научный центр психического здоровья». Федеральные клинические рекомендации по диагностике и лечению болезни Альцгеймера. Москва, 2013, 28 с. МКБ-10. Классификация психических и поведенческих расстройств. Клинические описания и указания по диагностике. Перевод на русский язык под редакцией: Ю.Л. Нуллера, С.Ю. Циркина. — Всемирная организация здравоохранения. — Санкт-Петербург, «Адис». — 1994. — С.46.

5. Buck MD, Atreja A, Brunker CP, et al. Potentially inappropriate medication prescribing in outpatient practices: prevalence and patient characteristics based on electronic health records. — Am J Geriatr Pharmacother. — 2009. — Vol.7. — P.84-92.

6. Chan DC, Chen JH, Kuo HK, et al. Drug-related problems (DRPs) identifed from geriatric medication safety review clinics. Arch Gerontol Geriatr. 2012;54(1):168-174.

7. Chrischilles E, Rubenstein L, Van Gilder R, Voelker M, Wright K, Wallace R. Risk factors for adverse drug events in older adults with mobility limitations in the community setting. J Am Geriatr Soc. 2007;55(1):29-34.

8. Corbett A., Francis P., Ballard C. Safety and EfŸcacy of Memantine Extended-Release in the moderate to severe Alzheimer’s disease. Dement Geriatr Cogn Disord. 2009;27:164–172.

9. Cosman K., Boyle L.L., Porsteinsson A.P. Memantine in the treatment of mild-to-moderate Alzheimer’s disease. Expert Opin. Pharmacother. (2007)8(2):203-214

10. Deardorff WJ, Feen E, Grossberg GT. Te use of cholinesterase inhibitors across all stages of Alzheimer’s disease. Drugs Aging 2015;32(7):537–47.

11. European Medicines Agency: Memantine hydrochloride—Summary of Product Characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000463/WC500058763.pdf. 2012. Accessed Mar 2013.

12. Ferris S, Ihl R, Robert P, Winblad B, Gatz G, Tennigkeit F, Gauthier S. 2009. Treatment effects of memantine on language in moderate to severe Alzheimer’s disease patients. 2009. Alzheimers Dement 5:369 — 374.

13. Gauthier S, Lof H, Cummings J. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer’s disease by memantine: a pooled data analysis. Int J Geriatr Psychiatry 2008;23(5):537–45

14. Gauthier S, Lof H, Cummings JImprovement in behavioural symptoms in patients with moderate to severe Alzheimer’s disease by memantine: a pooled data analysis. Int J Geriatr Psychiatry . 2008. 23:537 — 545.

15. Grossberg GT, Pejovic V, Miller ML, Graham SM. Memantine therapy of behavioral symptoms in community-dwelling patients with

16. Hansen RA, Gartlehner G, Webb AP, et al. Efcacy and safety of donepezil, galantamine and rivastigmine for the treatment of Alzheimer’s disease: a systemic review and meta-analysis. Clin Intervent Aging. 2008;3:211–225.

17. Herrmann N, Lanctảt KL, Hogan DB. Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. Alzheimer Res Ter. 2013;5(Suppl 1):S5.

18. Hill J, Fillit H, Tomas SK, Chang S: Functional impairment, healthcare costs and the prevalence of institutionalisation in patients with Alzheimer’s disease and other dementias. Pharmacoeconomics 2006;24:265-280

19. Howe E: Improving the quality of life in patients with Alzheimer’s disease. Psychiatry (Edgmont) 2008;5:51-56.

20. Ihl R, Frölich L, Winblad B., Schneider L., Burns A, MöLLER H.-Ü., WFSBP task force on treatment guidelines for alzheimer’s disease and other dementias World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Alzheimer’ s disease and other dementias. Te World Journal of Biological Psychiatry, 2011; 12: 2–32

21. Management of Alzheimer’s Disease Clinical Medicine Insights: Terapeutics 2013:5 95–102

22. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984). «Clinical diagnosis of Alzheimer’s disease: report of the NINCDSADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease». Neurology. 34 (7): 939–44.

23. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006(2):CD003154.

24. Molinuevo JL, Hernandez B: Assessment of the information provided by the medical specialist on Alzheimer’s disease and that retained by the patient caregivers. Neurologia 2012;27:453-471

25. NICE Submission of Evidence: Memantine. Donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer’s Disease Submission of evidence prepared for the national institute for health and clinical excellence by lundbeck

26. Nizri, E.; Hamra-Amitay, Y.; Sicsic, C.; Lavon, I.; Brenner, T. Anti-inflammatory properties of cholinergic up-regulation: A new role for acetylcholinesterase inhibitors. Neuropharmacology 2006, 50, 540–547.

27. Nordberg A. Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease. Alzheimer Dis Assoc Disord. 2006 AprJun;20(2 Suppl 1):S12-8.

28. Rountree S. D ., Chan W., Pavlik V. N., Darby E.J ., Siddiqui S. Doody R. S. Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease Alzheimers Res Ter2009 1:7

29. Salloway S; Mintzer J; Weiner M.F; Cummings J. L Disease-modifying therapies in Alzheimer’s disease Alzheimer and Dementia, March 2008, Volume 4, Issue 2, Pages 65–79

30. Seltzer B. Is long-term treatment of Alzheimer’s disea se with cholinesterase inhibitor therapy justifed? Drugs Aging. 2007;24:881–890.

31. Shanks M, Kivipelto M, Bullock R, et al. Cholinesterase inhibition: is there evidence for disease-modifying effects? Curr Med Res Opin. 2009; 25:2439–2446.

32. Small G, Dubois B: A review of compliance to treatment in Alzheimer’s disease: potential benefts of a transdermal patch. Curr Med Res Opin 2007;23:2705-2713.

33. Tangiisuran B, Wright J, Van der Cammen T, Rajkumar C. Adverse drug reactions in elderly: challenges in identifcation and improving preventative strategies. Age Ageing. 2009;38(4):358-359.

34. Tariot P.N., Farlow M.R., Grossberg G.T., Graham S.M., McDonald S., Gergel I. Memantine Treatment in Patients With Moderate to Severe Alzheimer Disease Already Receiving Donepezil A Randomized Controlled Trial. JAMA,January 21, 2004—Vol 291, No. 3: 317-324

35. Van der Steen JT. Dying with dementia: what we know afer more than a decade of research. J Alzheimers Dis 2010; 22: 37-55.

36. Vidal JS, Lacombe JM, Dartigues JF, et al. Evaluation of the impact of memantine treatment initiation on psychotropics use: a study from the French national health care database. Neuroepidemiology. 2008;31:193–200.

37. Wilcock GK, Ballard CG, Cooper JA, Lof H. Memantine for agitation/ aggression and psychosis in moderately severe to severe Alzheimer’s disease: a pooled analysis of 3 studies. J Clin Psychiatry. 2008;69: 341–348.

38. Wimo A, Winblad B, Stoefer A, et al. Resource utilisation and cost analysis of мemantine in patients with moderate to severe Alzheimer’s disease. Pharmacoeconomics. 2003;21:327–340

39. Winblad B, Jones RW, Wirth Y, et al.: Memantine in moderate to severe Alzheimer’s disease: a metaanalysis of randomised clinical trials. Dement Geriatr Cogn Disord 2007; 24: 20-27.

40. Wolf-Klein G, Pekmezaris R, Chin L and Weiner J. Conceptualizing Alzheimer’s disease as a terminal medical illness. — Am J Hosp Palliat Care. — 2007. — Vol.24. — P. 77-82.

41. Wolstenholme J, Fenn P, Gray A, Keene J, Jacoby R, Hope T: Estimating the relationship between disease progression and cost of care in dementia. — Br J Psychiatry. — 2002. — Vol.181. — P.36-42.

42. World Health Organization. Dementia: a public health priority. — WHO. — 2012. (www.who.int/mental_health/neurology/dementia/en/).6

43. Zanetti O, Solerte SB and Cantoni F. Life expectancy in Alzheimer’s disease (AD). — Arch Gerontol Geriatr. — 2009. — Vol.49. — P. 237-243.


Review

For citations:


Zalutskaya N.M., Beltceva I.A., Neznanov N.G. Tolerability of antidementive therapy: results of observational research. V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY. 2018;(2):117-124. (In Russ.) https://doi.org/10.31363/2313-7053-2018-2-117-124

Views: 597


ISSN 2313-7053 (Print)
ISSN 2713-055X (Online)